Shares in MannKind Corp. (NSDQ:MNKD) fell this week after the biopharmaceutical company missed expectations on Wall Street with its 1st quarter results.
The Valencia, Calif.-based company pared its losses to -$16.3 million on sales of $3 million for the 3 months ended March 31, for bottom-line growth of 53% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post MannKind shares dip after Q1 sales miss consensus appeared first on MassDevice.